SCIEX Biopharma meeting - Day 2: Gene therapy and vaccines
The technologies presented will be CE and LC-MS.
Over the course of 3 days (for 3 hours every day), you will discover the latest news from SCIEX, hear about new workflows from your colleagues in the industry and learn the tips and tricks to help you succeed with your instruments.
Agenda
10:00–10:10 Welcome and introduction (Jim Thorn, SCIEX)
10:10– 10:30 Influenza vaccine protein purity by CE (Patrick Buckley, Seqirus)
10:30–10:50 AAV characterization for gene therapy and vaccines (Ryan Hylands, Allergan)
10:50–11:20 Vaccine characterization by CE and LC-MS (Speaker to be confirmed)
11:20–11:40 Influenza vaccine particle analysis by CE (David Smith, AstraZeneca)
11:40–11:50 Break
11:50–12:20 CE training: tips and tricks for success (Marcin Moczulski, SCIEX)
12:20–12:40 LNP lipid composition by LC-MS (Sibylle Heidelberger, SCIEX)
12:40–13:00 Gene therapy and vaccines by LC-MS (Speaker to be confirmed)
13:00–13:10 Wrap-up and Q&A
13:10–17:00 Private chat rooms for further discussion:book online
Your host for the day: Jim Thorn (Market Development Team Manager, Pharma & Biopharma, EMEAI, SCIEX)
Jim completed his PhD in the field of Medicine in 1991 at St. Bartholomew’s Hospital, University of London, investigating genetic predisposition to human cardiovascular disease. Jim then joined Beckman Coulter in 1998. Over the course of 15 years, Jim was responsible for European and Global Capillary Electrophoresis Product Management. In 2014, Jim joined SCIEX when the CE business from Beckman Coulter was integrated into SCIEX, and he now leads the Pharma and Biopharma team responsible for the promotion of CE and LC-MS technologies through scientific collaboration.
